MedPath

Feasibility and efficacy of triplet regimen in transplant-ineligible NDMM patients

Not Applicable
Conditions
Multiple myeloma
Registration Number
JPRN-UMIN000027978
Lead Sponsor
Hyogo College of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1) Smoldering or IgM myeloma, solitary plasmacytoma, plasma cell leukemia, POEMS syndrome, WM 2) CNS involvement 3) HIV+, HBs Ag+, or HCV Ab+ 4) Severe abnormality in the liver, kidney, cardiac, or pulmonary functions. Severe diabetes, hypertension, or infection. 5) Severe psychotic disorders.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
CR rate after the completion of the induction therapy
Secondary Outcome Measures
NameTimeMethod
1) Response rate (VGPR, MRD negative) after the completion of the induction therapy 2) Adverse events 3) Quality of life at the time of the enrollment, after 6 courses of the induction therapy, and after the completion of the induction therapy
© Copyright 2025. All Rights Reserved by MedPath